Financhill
Buy
66

AMLX Quote, Financials, Valuation and Earnings

Last price:
$7.67
Seasonality move :
39.3%
Day range:
$7.21 - $7.73
52-week range:
$1.76 - $7.73
Dividend yield:
0%
P/E ratio:
21.03x
P/S ratio:
6.38x
P/B ratio:
3.40x
Volume:
1.7M
Avg. volume:
1.7M
1-year change:
236.84%
Market cap:
$684.6M
Revenue:
$87.4M
EPS (TTM):
-$3.11

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AMLX
Amylyx Pharmaceuticals
-- -$0.46 -100% -57.63% $11.63
ELAN
Elanco Animal Health
$1.1B $0.13 0.16% 407.4% $14.95
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.43 -- -95.63% $7.00
VERA
Vera Therapeutics
-- -$0.81 -- -37.66% $63.36
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AMLX
Amylyx Pharmaceuticals
$7.68 $11.63 $684.6M 21.03x $0.00 0% 6.38x
ELAN
Elanco Animal Health
$14.90 $14.95 $7.4B 20.14x $0.00 0% 1.67x
NBY
NovaBay Pharmaceuticals
$0.69 $0.85 $4M -- $0.00 0% 0.16x
OGEN
Oragenics
$1.42 $1.00 $1M -- $0.00 0% 0.45x
TOVX
Theriva Biologics
$0.50 $7.00 $4.1M -- $0.00 0% 0.33x
VERA
Vera Therapeutics
$23.82 $63.36 $1.5B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AMLX
Amylyx Pharmaceuticals
-- 0.090 -- 6.23x
ELAN
Elanco Animal Health
40.89% 2.904 84.31% 1.22x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
VERA
Vera Therapeutics
-- 2.616 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AMLX
Amylyx Pharmaceuticals
-- -$37.8M -109.32% -109.32% 6113.38% -$39.8M
ELAN
Elanco Animal Health
$684M $121M 3.36% 6.02% 8.38% -$69M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M
VERA
Vera Therapeutics
-- -$57.2M -- -- -- -$39.8M

Amylyx Pharmaceuticals vs. Competitors

  • Which has Higher Returns AMLX or ELAN?

    Elanco Animal Health has a net margin of -17476.92% compared to Amylyx Pharmaceuticals's net margin of 5.62%. Amylyx Pharmaceuticals's return on equity of -109.32% beat Elanco Animal Health's return on equity of 6.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMLX
    Amylyx Pharmaceuticals
    -94.47% -$0.42 $164.8M
    ELAN
    Elanco Animal Health
    57.34% $0.13 $10.7B
  • What do Analysts Say About AMLX or ELAN?

    Amylyx Pharmaceuticals has a consensus price target of $11.63, signalling upside risk potential of 51.37%. On the other hand Elanco Animal Health has an analysts' consensus of $14.95 which suggests that it could grow by 0.37%. Given that Amylyx Pharmaceuticals has higher upside potential than Elanco Animal Health, analysts believe Amylyx Pharmaceuticals is more attractive than Elanco Animal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMLX
    Amylyx Pharmaceuticals
    8 1 0
    ELAN
    Elanco Animal Health
    7 7 0
  • Is AMLX or ELAN More Risky?

    Amylyx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Elanco Animal Health has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.489%.

  • Which is a Better Dividend Stock AMLX or ELAN?

    Amylyx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elanco Animal Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals pays -- of its earnings as a dividend. Elanco Animal Health pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMLX or ELAN?

    Amylyx Pharmaceuticals quarterly revenues are -$665K, which are smaller than Elanco Animal Health quarterly revenues of $1.2B. Amylyx Pharmaceuticals's net income of -$35.9M is lower than Elanco Animal Health's net income of $67M. Notably, Amylyx Pharmaceuticals's price-to-earnings ratio is 21.03x while Elanco Animal Health's PE ratio is 20.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals is 6.38x versus 1.67x for Elanco Animal Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMLX
    Amylyx Pharmaceuticals
    6.38x 21.03x -$665K -$35.9M
    ELAN
    Elanco Animal Health
    1.67x 20.14x $1.2B $67M
  • Which has Higher Returns AMLX or NBY?

    NovaBay Pharmaceuticals has a net margin of -17476.92% compared to Amylyx Pharmaceuticals's net margin of -49.65%. Amylyx Pharmaceuticals's return on equity of -109.32% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMLX
    Amylyx Pharmaceuticals
    -94.47% -$0.42 $164.8M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About AMLX or NBY?

    Amylyx Pharmaceuticals has a consensus price target of $11.63, signalling upside risk potential of 51.37%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Amylyx Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Amylyx Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMLX
    Amylyx Pharmaceuticals
    8 1 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is AMLX or NBY More Risky?

    Amylyx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock AMLX or NBY?

    Amylyx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMLX or NBY?

    Amylyx Pharmaceuticals quarterly revenues are -$665K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Amylyx Pharmaceuticals's net income of -$35.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Amylyx Pharmaceuticals's price-to-earnings ratio is 21.03x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals is 6.38x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMLX
    Amylyx Pharmaceuticals
    6.38x 21.03x -$665K -$35.9M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns AMLX or OGEN?

    Oragenics has a net margin of -17476.92% compared to Amylyx Pharmaceuticals's net margin of --. Amylyx Pharmaceuticals's return on equity of -109.32% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AMLX
    Amylyx Pharmaceuticals
    -94.47% -$0.42 $164.8M
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About AMLX or OGEN?

    Amylyx Pharmaceuticals has a consensus price target of $11.63, signalling upside risk potential of 51.37%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Amylyx Pharmaceuticals, analysts believe Oragenics is more attractive than Amylyx Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMLX
    Amylyx Pharmaceuticals
    8 1 0
    OGEN
    Oragenics
    0 1 0
  • Is AMLX or OGEN More Risky?

    Amylyx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock AMLX or OGEN?

    Amylyx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMLX or OGEN?

    Amylyx Pharmaceuticals quarterly revenues are -$665K, which are larger than Oragenics quarterly revenues of --. Amylyx Pharmaceuticals's net income of -$35.9M is lower than Oragenics's net income of -$2.2M. Notably, Amylyx Pharmaceuticals's price-to-earnings ratio is 21.03x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals is 6.38x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMLX
    Amylyx Pharmaceuticals
    6.38x 21.03x -$665K -$35.9M
    OGEN
    Oragenics
    0.45x -- -- -$2.2M
  • Which has Higher Returns AMLX or TOVX?

    Theriva Biologics has a net margin of -17476.92% compared to Amylyx Pharmaceuticals's net margin of --. Amylyx Pharmaceuticals's return on equity of -109.32% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AMLX
    Amylyx Pharmaceuticals
    -94.47% -$0.42 $164.8M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About AMLX or TOVX?

    Amylyx Pharmaceuticals has a consensus price target of $11.63, signalling upside risk potential of 51.37%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1294.42%. Given that Theriva Biologics has higher upside potential than Amylyx Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Amylyx Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMLX
    Amylyx Pharmaceuticals
    8 1 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is AMLX or TOVX More Risky?

    Amylyx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock AMLX or TOVX?

    Amylyx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMLX or TOVX?

    Amylyx Pharmaceuticals quarterly revenues are -$665K, which are larger than Theriva Biologics quarterly revenues of --. Amylyx Pharmaceuticals's net income of -$35.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, Amylyx Pharmaceuticals's price-to-earnings ratio is 21.03x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals is 6.38x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMLX
    Amylyx Pharmaceuticals
    6.38x 21.03x -$665K -$35.9M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M
  • Which has Higher Returns AMLX or VERA?

    Vera Therapeutics has a net margin of -17476.92% compared to Amylyx Pharmaceuticals's net margin of --. Amylyx Pharmaceuticals's return on equity of -109.32% beat Vera Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AMLX
    Amylyx Pharmaceuticals
    -94.47% -$0.42 $164.8M
    VERA
    Vera Therapeutics
    -- -$0.81 --
  • What do Analysts Say About AMLX or VERA?

    Amylyx Pharmaceuticals has a consensus price target of $11.63, signalling upside risk potential of 51.37%. On the other hand Vera Therapeutics has an analysts' consensus of $63.36 which suggests that it could grow by 165.98%. Given that Vera Therapeutics has higher upside potential than Amylyx Pharmaceuticals, analysts believe Vera Therapeutics is more attractive than Amylyx Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMLX
    Amylyx Pharmaceuticals
    8 1 0
    VERA
    Vera Therapeutics
    9 1 0
  • Is AMLX or VERA More Risky?

    Amylyx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vera Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock AMLX or VERA?

    Amylyx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vera Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals pays -- of its earnings as a dividend. Vera Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMLX or VERA?

    Amylyx Pharmaceuticals quarterly revenues are -$665K, which are larger than Vera Therapeutics quarterly revenues of --. Amylyx Pharmaceuticals's net income of -$35.9M is higher than Vera Therapeutics's net income of -$51.7M. Notably, Amylyx Pharmaceuticals's price-to-earnings ratio is 21.03x while Vera Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals is 6.38x versus -- for Vera Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMLX
    Amylyx Pharmaceuticals
    6.38x 21.03x -$665K -$35.9M
    VERA
    Vera Therapeutics
    -- -- -- -$51.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock